The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.75
Bid: 31.50
Ask: 32.00
Change: -0.25 (-0.78%)
Spread: 0.50 (1.587%)
Open: 31.75
High: 31.75
Low: 31.75
Prev. Close: 32.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational and Corporate Update

30 Oct 2018 07:00

RNS Number : 5753F
Duke Royalty Limited
30 October 2018
 

30 October 2018

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

 

Operational and Corporate Update

 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to announce that the monthly payments made to the Company by its royalty partners Temarca B.V. ("Temarca") and Lynx Equity (U.K.) Limited ("Lynx UK") under their respective royalty agreements have both increased by the maximum 6% at their first annual adjustment, and have been backdated to their respective annual adjustment dates. The royalties will remain at that level until the next adjustment date under the terms of the agreements.

 

The Company also announces that Steven Russo and Ajay Shivdasani have joined the investment team.

 

In addition, the Company announces that it will release its interim results for the 6 months ended 30 September 2018 during the first week of December.

 

Annual adjustments

 

Each of Duke's royalty partners are subject to an annual adjustment, which triggers a reset of the monthly payment amount due to Duke, subject to a collar (a maximum adjustment up or down). The reset is calculated once a year, each year for the life of the royalty agreement, based on the gross revenue growth (or decline) of the royalty partner over the preceding twelve months.

The annual adjustments for Duke's first two Royalty Partners, Lynx UK and Temarca have now been confirmed. As preliminarily announced on 8 May 2018, Temarca and Lynx UK were tracking above the top end of the annual adjustment range, and the Company is pleased to report that both partners have now posted revenue growth of above 6% for their respective adjustment periods. This has therefore led to an increase in the monthly payments due to Duke by 6% in both cases. Following these adjustments Temarca's payments to Duke will now total approximately £1.0 million annually (starting July 2018) and Lynx UK's will now total approximately £1.25 million annually (starting August 2018).

With regard to Duke's other partners, the first adjustment date for both Trimite and Brownhills is on 31 March 2019. Based on management accounts received by Duke for the period to the end of September 2018, the year on year revenue performance for Trimite is currently up by more than 6% (based on a six-month period) and for Brownhills it is up by more than 10% (based on a ten-month period). As such, Duke remains confident of a positive reset event as and when these two partners complete their first adjustment periods.

Neil Johnson, CEO of Duke Royalty, commented:

"It is great to see the solid revenue growth of our royalty partners, Temarca and Lynx, which has led to the annual royalty distributions from each being substantially increased. I am also hopeful that Duke's shareholders will see a positive adjustment in 2019 from our third and fourth royalty partners, Trimite and Brownhills.

"This news encapsulates how our business model benefits investors. By partnering with private businesses looking for growth capital, Duke is well placed to benefit from their success and we are delighted to be receiving higher royalty payments from our inaugural investments. Thanks to Duke's high operating leverage, these types of positive annual adjustments, combined with future additional capital deployments, can produce a higher dividend pay-out to the Company's shareholders.

 

"I am pleased to also be able to announce the new appointments of Steve Russo and Ajay Shivdasani, whose significant investment experience has strengthened the Company's investment team and provide expertise necessary to grow the Company."

New appointments to investment team

The Company would like to welcome Steven Russo and Ajay Shivdasani who have joined Abingdon Capital Corporation, Duke's service provider, on a full-time basis. They will be dedicated to providing support to Duke and will add to the investment evaluation and due diligence resources of Duke.

Steven Russo has spent the past six years working primarily on mezzanine debt and select equity growth capital transactions as a former Vice President at Difference Capital Financial Inc. Steven has gained valuable transactional and due diligence experience working in the alternative finance sector, as well as investment monitoring and oversight. Before this, Steven became a qualified Canadian securities lawyer at Wildeboer Dellelce LLP in Toronto.

Steven has a dual J.D. and MBA degree from Queen's University and holds a Bachelor of Science degree, with honours, from York University.

Ajay Shivdasani had over three years of private-equity LBO transaction and deal origination experience at DW Healthcare Partners. Ajay's private equity training and expertise, along with a complementary origination network will benefit the Company. Mr. Shivdasani also worked for four years at Oliver Wyman, a global management consulting firm, where he advised leading financial services organizations. Mr. Shivdasani also led the corporate development function of Altima Dental, the 2nd largest dental service organization in Canada.

Ajay holds an MBA Degree from INSEAD as well as a BASc in Industrial Engineering from the University of Toronto.

 

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson/ Charlie Cannon-Brookes

 

+44 (0) 1481 741 240

Grant Thornton UK LLP 

(Nominated Adviser)

Colin Aaronson/ Samantha

Harrison

 

+44 (0) 20 7383 5100

 

Cenkos Securities plc 

(Joint Broker)

 

Julian Morse/ Michael Johnson

+44 (0) 207 397 8900

Mirabaud Securities Limited

(Joint Broker)

 

Peter Krens/ Edward Haig-Thomas

 

+44 (0) 20 3167 7222

Redleaf Communications

(PR)

 

Elisabeth Cowell/ Ian Silvera / Tom Carnegie

+44 (0) 20 3757 6880

Dukeroyalty@redleafpr.com

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDFKCDBPBDDPKB
Date   Source Headline
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.